Monte Rosa Therapeutics (GLUE) Return on Capital Employed: 2023-2025
Historic Return on Capital Employed for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to 0.02%.
- Monte Rosa Therapeutics' Return on Capital Employed rose 47.00% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 47.00%. This contributed to the annual value of -0.38% for FY2024, which is N/A change from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Return on Capital Employed of 0.02% as of Q3 2025, which was down 45.35% from 0.04% recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Return on Capital Employed ranged from a high of 0.04% in Q2 2025 and a low of -0.62% during Q4 2023.
- In the last 3 years, Monte Rosa Therapeutics' Return on Capital Employed had a median value of -0.41% in 2024 and averaged -0.31%.
- Data for Monte Rosa Therapeutics' Return on Capital Employed shows a peak YoY soared of 58bps (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Return on Capital Employed stood at -0.62% in 2023, then rose by 25bps to -0.37% in 2024, then skyrocketed by 47bps to 0.02% in 2025.
- Its last three reported values are 0.02% in Q3 2025, 0.04% for Q2 2025, and -0.01% during Q1 2025.